Vir Biotechnology Inc (VIR)
Days of sales outstanding (DSO)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | 300.88 | 1.90 | 1.42 | 3.06 | — | 0.65 | — | — | — | ||||
| DSO | days | — | — | — | — | — | — | 1.21 | 191.95 | 257.60 | 119.36 | — | 565.40 | — | — | — |
December 31, 2023 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) for Vir Biotechnology Inc have shown a significant improvement since Q1 2022 when it was 191.95 days. In Q2 2022, the DSO decreased substantially to 1.21 days, indicating a more efficient collection of accounts receivable. Unfortunately, there is missing data for the subsequent periods, making it challenging to assess the trend going forward. However, the substantial reduction in DSO from Q1 to Q2 2022 suggests that the company has likely implemented more effective credit and collection practices, leading to faster conversion of sales into cash. Monitoring the DSO trend in future quarters will be crucial to evaluate the overall effectiveness of the company's accounts receivable management.
Peer comparison
Dec 31, 2023